2nd Oral Oncolytics Conference
October 28, 2015
Loreen Brown, SVP of Product Management and Not-for-Profit Operations, Lash Group, and Ana Stojanovska, Sr. Director, Xcenda, co-present "Drive Access and Adherence through Best-in-Class Patient and Provider Support Programs."
Key factors to ensuring product access include provider knowledge and the patient’s ability and willingness to adhere to a therapy. This session will explore market access challenges – both current and future - facing oral oncolytics and provide insight on how manufacturers are developing effective support services to address these issues. Topics include:
- Overview of payer and provider challenges for oral oncology products
- Impact of ACA and Health Insurance Exchanges on the oncology landscape
- Considerations for co-pay support programs to improve access
- Development of customer-centric, integrated learning and support experiences to enhance patient adherence
Studies have shown that oral oncolytics hold some of the highest potential for ROI, currently making up to 35% of the current oncology pipeline.* Yet the patient abandonment rates for these products are incredibly high, due to out-of-pocket cost share and patient non-adherence. In order to maximize your product’s potential, join us at CBI’s 2nd Annual Oral Oncolytics Summit and hear from key stakeholders on critical issues surrounding patient initiation, access, reimbursement and adherence.